Deerfield Management Company, L.P.'s Form 4 filing
ARS Pharmaceuticals, Inc. (SPRY) · filed Nov 13, 2024
- Accession no.
- 0001193805-24-001348
- Filed
- Nov 13, 2024, 8:16 PM ET
- Trade date
- Nov 11-12, 2024
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 8 non-derivative transactions. Open-market sales total $10.1M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Deerfield Management Company, L.P.CIK 0001009258 | 10% Owner |
| Flynn James ECIK 0001352546 | 10% Owner |
| Deerfield Private Design Fund III, L.P.CIK 0001603333 | 10% Owner |
| Deerfield Mgmt III, L.P.CIK 0001610540 | 10% Owner |
| Deerfield Private Design Fund IV, L.P.CIK 0001680307 | 10% Owner |
| Deerfield Mgmt IV, L.P.CIK 0001713467 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 11, 2024 | Class A Common Stock | SSaleDisposed | −40,596 | $17.45F1 | −$708,400.2 | 5,498,368 | Indirect | |
| Nov 11, 2024 | Class A Common Stock | SSaleDisposed | −40,596 | $17.45F1 | −$708,400.2 | 5,498,367 | Indirect | |
| Nov 11, 2024 | Class A Common Stock | SSaleDisposed | −223,632 | $18.15F4 | −$4,058,920.8 | 5,274,736 | Indirect | |
| Nov 11, 2024 | Class A Common Stock | SSaleDisposed | −223,632 | $18.15F4 | −$4,058,920.8 | 5,274,735 | Indirect | |
| Nov 12, 2024 | Class A Common Stock | SSaleDisposed | −7,853 | $17.16F5 | −$134,757.48 | 5,266,883 | Indirect | |
| Nov 12, 2024 | Class A Common Stock | SSaleDisposed | −7,854 | $17.16F5 | −$134,774.64 | 5,266,881 | Indirect | |
| Nov 12, 2024 | Class A Common Stock | SSaleDisposed | −9,554 | $17.77F6 | −$169,774.58 | 5,257,329 | Indirect | |
| Nov 12, 2024 | Class A Common Stock | SSaleDisposed | −9,553 | $17.77F6 | −$169,756.81 | 5,257,328 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.90 to $17.90, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1, 4, 5 and 6 of this Form 4.
Referenced by the price of 2 transactions in Table I.
- F4
The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.91 to $18.51, inclusive.
Referenced by the price of 2 transactions in Table I.
- F5
The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.68 to $17.65, inclusive.
Referenced by the price of 2 transactions in Table I.
- F6
The price reported in Column 4 represents a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.69 to $17.82, inclusive.
Referenced by the price of 2 transactions in Table I.
Remarks
Jonathan Isler, Attorney-in-Fact: Power of Attorney, which is hereby incorporated by reference to Exhibit 24 to a Form 3 with regard to BiomX Inc. filed with the Securities and Exchange Commission on March 19, 2024 by Deerfield Private Design Fund III, L.P., Deerfield Private Design Fund IV, L.P., Deerfield Mgmt III, L.P., Deerfield Mgmt IV, L.P., Deerfield Management Company, L.P. and James E. Flynn.